Needham & Company Maintain High Conviction for Sarepta (SRPT) Eteplirsen Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Sarepta (SRPT) Conditional-Approval Thesis Unchanged, Roth Capital Says
November 6, 2015 8:17 AM ESTRoth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT), saying their conditional-approval thesis remains unchanged.
Chattopadhyay commented, "A new therapy is not considered available therapy if granted accelerated approval based on a surrogate or... More
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c
November 5, 2015 7:04 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.11), $0.07 better than the analyst estimate of ($1.18).
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... More